The concurrent chemoradiation paradigm - General principles

Nature Clinical Practice Oncology

Volumn 4, Issue 2, 2007, Pages 86-100

  Seiwert, Tanguy Y ^a   Salama, Joseph K ^b   Vokes, Everett E ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ANTIINFECTIVE AGENT; BEVACIZUMAB; BROXURIDINE; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; EARLY GROWTH RESPONSE FACTOR 1; ERLOTINIB; ETOPOSIDE; FLUOROURACIL; GEFITINIB; GEMCITABINE; HYDROXYUREA; IRINOTECAN; MISONIDAZOLE; MITOMYCIN C; OXALIPLATIN; PACLITAXEL; PALIFERMIN; PEMETREXED; TAXANE DERIVATIVE; TEMOZOLOMIDE; TIRAPAZAMINE; TNFERADE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN INHIBITOR; VATALANIB;

BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CELL SYNCHRONIZATION; CLINICAL TRIAL; COLORECTAL CANCER; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG PENETRATION; DYSGEUSIA; ESOPHAGITIS; ESOPHAGUS CANCER; FATIGUE; FEVER; GASTROINTESTINAL TOXICITY; GLIOMA; HEAD AND NECK CANCER; HUMAN; HYPOTENSION; INTENSITY MODULATED RADIATION THERAPY; LOW DRUG DOSE; LUNG CANCER; META ANALYSIS; MOLECULAR THERAPY; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; MUSCLE CRAMP; OTOTOXICITY; PANCREAS CANCER; PNEUMONIA; PRIORITY JOURNAL; PROTEIN TARGETING; RADIATION DOSE; RADIOSENSITIVITY; RADIOSENSITIZATION; RECTUM CANCER; REVIEW; SIDE EFFECT; SKIN TOXICITY; SNEEZING; SOLID TUMOR; SYSTEMATIC REVIEW; TREATMENT FAILURE; WEIGHT REDUCTION; XEROSTOMIA;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; HUMANS; NEOPLASMS;

EID: 33846708225     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc0714     Document Type: Review

References (132)

1. Steel GG and Peckham MJ (1979) Exploitable mechanisms in combined radiotherapy-chemotherapy: The concept of additivity. Int J Radiat Oncol Biol Phys 5: 85-91
2. Brizel DM et al. (2000) Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 18: 3339-3345
3. Buentzel J et al. (2006) Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: A randomized placebo-controlled phase III study. Int J Radiat Oncol Biol Phys 64: 684-691
4. Komaki R et al. (2004) Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: Report of a randomized comparative trial. Int J Radiat Oncol Biol Phys 58:1369-1377
5. Malik R et al. (2005) Meta-analysis of the effect of amifostine on response rates in advanced non-small cell lung cancer patients treated on randomized trials. Int J Radiat Oncol Biol Phys 63 (Suppl 1): S117
6. Sasse AD et al. (2006) Amifostine reduces side effects and improves complete response rate during radiotherapy: Results of a meta-analysis. Int J Radiat Oncol Biol Phys 64: 784-791
7. Grdina DJ et al. (2002) Radioprotectants: Current status and new directions. Oncology 63 (Suppl 2): S2-S10
8. Stiff PJ et al. (2006) Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting. J Clin Oncol [doi: 10.1200/ JCO.2005.02.8340]
9. Rosen LS et al. (2006) Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy. J Clin Oncol 24: 5194-5200
10. Giocanti N et al. (1993) DNA repair and cell cycle interactions in radiation sensitization by the topoisomerase II poison etoposide. Cancer Res 53: 2105-2111
11. Hennequin C and Favaudon V (2002) Biological basis for chemo-radiotherapy interactions. Eur J Cancer 38: 223-230
12. Chou TC and Talalay P (1984) Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55
13. Reynolds CP and Maurer BJ (2005) Evaluating response to antineoplastic drug combinations in tissue culture models. Methods Mol Med 110: 173-183
14. Teicher BA (2003) Assays for in vitro and in vivo synergy. Methods Mol Med 85: 297-321
15. White DB et al. (2003) A new nonlinear mixture response surface paradigm for the study of synergism: A three drug example. Curr Drug Metab 4: 399-409
16. Coleman CN (1988) Hypoxia in tumors: A paradigm for the approach to biochemical and physiologic heterogeneity. J Natl Cancer Inst 80: 310-317
17. Gray LH et al. (1953) The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 26: 638-648
18. Kumar P (2000) Tumor hypoxia and anemia: Impact on the efficacy of radiation therapy. Semin Hematol 37: 4-8
19. Overgaard J et al. (1989) Misonidazole combined with split-course radiotherapy in the treatment of invasive carcinoma of larynx and pharynx: Report from the DAHANCA 2 study. Int J Radiat Oncol Biol Phys 16: 1065-1068
20. Moulder JE and Rockwell S (1984) Hypoxic fractions of solid tumors: experimental techniques, methods of analysis, and a survey of existing data. Int J Radiat Oncol Biol Phys 10: 695-712
21. Terasima T and Tolmach LJ (1963) X-ray sensitivity and DNA synthesis in synchronous populations of HeLa cells. Science 140: 490-492
22. Fowler JF and Lindstrom MJ (1992) Loss of local control with prolongation in radiotherapy. Int J Radiat Oncol Biol Phys 23: 457-467
23. Trott KR and Kummermehr J (1985) What is known about tumour proliferation rates to choose between accelerated fractionation or hyperfractionation? Radiother Oncol 3: 1-9
24. Krause M et al. (2005) Decreased repopulation as well as increased reoxygenation contribute to the improvement in local control after targeting of the EGFR by C225 during fractionated irradiation. Radiother Oncol 76: 162-167
25. Grillo-Ruggieri F and Mantello G (2004) Is one Gy equal to one Gy after treatment interruptions? Rays 29: 275-278
26. Schmidt-Ullrich RK et al. (1999) Molecular mechanisms of radiation-induced accelerated repopulation. Radiat Oncol Investig 7: 321-330
27. West CM et al. (1997) The independence of intrinsic radiosensitivity as a prognostic factor for patient response to radiotherapy of carcinoma of the cervix. Br J Cancer 76: 1184-1190
28. Deacon J et al. (1984) The radioresponsiveness of human tumours and the initial slope of the cell survival curve. Radiother Oncol 2: 317-323
29. Dey S et al. (2003) Low-dose fractionated radiation potentiates the effects of paclitaxell in wild-type and mutant p53 head and neck tumor cell lines. Clin Cancer Res 9: 1557-1565
30. Nix PA et al. (2004) Radioresistant laryngeal cancer: Beyond the TNM stage. Clin Otolaryngol Allied Sci 29: 105-114
31. Smith BD and Haffty BG (1999) Molecular markers as prognostic factors for local recurrence and radioresistance in head and neck squamous cell carcinoma. Radiat Oncol Investig 7: 125-144
32. Aebersold DM et al. (2001) Involvement of the hepatocyte growth factor/ scatter factor receptor c-met and of BcI-xL in the resistance of oropharyngeal cancer to ionizing radiation. Int J Cancer 96: 41-54
33. Uchida D et al. (2001) Role of HGF/c-met system in invasion and metastasis of oral squamous cell carcinoma cells in vitro and its clinical significance. Int J Cancer 93: 489-496
34. Khodarev NN et al. (2004) STAT1 is overexpressed in tumors selected for radioresistance and confers protection from radiation in transduced sensitive cells. Proc Natl Acad Sci USA 101: 1714-1719
35. Bennett CB et al. (1993) Lethality induced by a single site-specific double-strand break in a dispensable yeast plasmid. Proc Natl Acad Sci USA 15: 13-17
36. Ward JF (1998) Nature of lesions formed by ionising radiation. In DNA damage and repair: DNA repair in higher eukaryotes, 65-84 (Eds Nickoloff JA and Hoekstra MF). Totowa, NJ: Humana Press
37. Begg AC (1990) Cisplatin and radiation: Interaction probabilities and therapeutic possibilities. Int J Radiat Oncol Biol Phys 19: 1183-1189
38. Yang LX et al. (1995) Production of DNA doublestrand breaks by interactions between carboplatin and radiation: A potential mechanism for radiopotentiation. Radiat Res 143: 309-315
39. Sinclair WK and Morton RA (1966) X-ray sensitivity during the cell generation cycle of cultured Chinese hamster cells. Radiat Res 29: 450-474
40. Terasima T and Tolmach LJ (1961) Changes in x-ray sensitivity of HeLa cells during the division cycle. Nature 190: 1210-1211
41. Wilson GD et al. (2006) Biologic basis for combining drugs with radiation. Semin Radiat Oncol 16: 2-9
42. Hei TK et al. (1994) Taxol and ionizing radiation: Interaction and mechanisms. Int J Radiat Oncol Biol Phys 29: 267-271
43. Stromberg JS et al. (1995) Lack of radiosensitization after paclitaxel treatment of three human carcinoma cell lines. Cancer 75: 2262-2268
44. Vaupel P (2004) Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol 14: 198-206
45. Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732
46. Milas L et al. (1995) Tumor reoxygenation as a mechanism of taxol-induced enhancement of tumor radioresponse. Acta Oncol 34: 409-412
47. Kim JJ and Tannock IF (2005) Repopulation of cancer cells during therapy: An important cause of treatment failure. Nat Rev Cancer 5: 516-525
48. Liang K et al. (2003) The epidermal growth factor receptor mediates radioresistance. Int J Radiat Oncol Biol Phys 57: 246-254
49. Bonner JA et al. (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354: 567-578
50. Spring PM et al. (2004) Low dose fractionated radiation potentiates the effects of taxotere in nude mice xenografts of squamous cell carcinoma of head and neck. Cell Cycle 3: 479-485
51. Vokes EE and Weichselbaum RR (1990) Concomitant chemoradiotherapy: rationale and clinical experience in patients with solid tumors. J Clin Oncol 8: 911-934
52. Richmond RC (1984) Toxic variability and radiation sensitization by dichlorodiammineplatinum(II) complexes in Salmonella typhimurium cells. Radiat Res 99: 596-608
53. Yang LX et al. (1995) Irradiation enhances cellular uptake of carboplatin. Int J Radiat Oncol Biol Phys 33: 641-646
54. Amorino GP et al. (1999) Radiopotentiation by the oral platinum agent, JM216: Role of repair inhibition. Int J Radiat Oncol Biol Phys 44: 399-405
55. Moreland NJ et al. (1999) Modulation of drug resistance mediated by loss of mismatch repair by the DNA polymerase inhibitor aphidicolin. Cancer Res 59: 2102-2106
56. Dolling JA et al. (1999) Cisplatin-modification of DNA repair and ionizing radiation lethality in yeast, Saccharomyces cerevisiae. Mutat Res 433: 127-136
57. Lawrence TS et al. (1997) Fluoropyrimidine-radiation interactions in cells and tumors. Semin Radiat Oncol 7: 260-266
58. McGinn CJ and Lawrence TS (2001) Recent advances in the use of radiosensitizing nucleosides. Semin Radiat Oncol 11: 270-280
59. Pinedo HM and Peters GF (1988) Fluorouracil: Biochemistry and pharmacology. J Clin Oncol 6: 1653-1664
60. Sawada N et al. (1999) X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res 5: 2948-2953
61. Hui YF and Reitz J (1997) Gemcitabine: A cytidine analogue active against solid tumors. Am J Health Syst Pharm 54: 162-170
62. Crane CH et al. (2002) Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? Int J Radiat Oncol Biol Phys 52: 1293-1302
63. Blackstock AW et al. (2005) Initial pulmonary toxicity evaluation of chemoradiotherapy (CRT) utilizing 74 Gy 3-dimensional (3-D) thoracic radiation in stage III non-small cell lung cancer (NSCLC): A Cancer and Leukemia Group B (CALGB) randomized phase II trial [abstract #7060]. Presented at the 2005 ASCO annual meeting, Orlando, FL
64. Talamonti MS et al. (2006) A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol 13: 150-158
65. Lawrence TS et al. (2003) The mechanism of action of radiosensitization of conventional chemotherapeutic agents. Semin Radiat Oncol 13: 13-21
66. Lawrence TS et al. (1997) Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2′,2′-difluoro-2′-deoxycytidine (Gemcitabine). Clin Cancer Res 3: 777-782
67. Shewach DS and Lawrence TS (1996) Gemcitabine and radiosensitization in human tumor cells. Invest New Drugs 14: 257-263
68. Bischof M et al. (2002) Interaction of pemetrexed disodium (ALIMTA, multitargeted antifolate) and irradiation in vitro. Int J Radiat Oncol Biol Phys 52: 1381-1388
69. Bischof M et al. (2003) Radiosensitization by pemetrexed of human colon carcinoma cells in different cell cycle phases. Int J Radiat Oncol Biol Phys 57: 289-292
70. Seiwert TY et al. (2005) A phase I dose-escalating study of combination pemetrexed-based chemotherapy and concomitant radiotherapy for locally advanced or metastatic non-small cell lung or esophageal cancer [abstract #7062]. Presented at the 2005 ASCO annual meeting, Orlando, FL
71. Vokes EE et al. (1992) Hydroxyurea with concomitant radiotherapy for locally advanced head and neck cancer. Semin Oncol 19: 53-58
72. Kuo ML et al. (1997) The interaction of hydroxyurea and ionizing radiation in human cervical carcinoma cells. Cancer J Sci Am 3: 163-173
73. Prados MD et al. (1998) Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors. Int J Radiat Oncol Biol Phys 40: 57-63
74. Leyden D et al. (2000) Hydroxyurea and trimidox enhance the radiation effect in human pancreatic adenocarcinoma cells. Anticancer Res 20: 133-138
75. Schiff PB and Horwitz SB (1980) Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 77: 1561-1565
76. Hennequin C et al. (1995) S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells. Br J Cancer 71: 1194-1198
77. Steel GG (1994) Cell synchronization unfortunately may not benefit cancer therapy. Radiother Oncol 32: 95-97
78. Ingram ML and Redpath JL (1997) Subadditive interaction of radiation and Taxol in vitro. Int J Radiat Oncol Biol Phys 37: 1139-1144
79. Heinrich MC et al. (1998) DNA cross-linker-induced G2/M arrest in group C Fanconi anemia lymphoblasts reflects normal checkpoint function. Blood 91: 275-287
80. Sugiyama K et al. (2000) UCN-01 selectively enhances mitomycin C cytotoxicity in p53 defective cells which is mediated through S and/or G(2) checkpoint abrogation. Int J Cancer 85: 703-709
81. Budach W et al. (2002) Mitomycin C in combination with radiotherapy as a potent inhibitor of tumour cell repopulation in a human squamous cell carcinoma. Br J Cancer 86: 470-476
82. Wouters BG et al. (1999) Tirapazamine: A new drug producing tumor specific enhancement of platinum-based chemotherapy in non-small-cell lung cancer. Ann Oncol 10 (Suppl 5): S29-S33
83. Brown JM and Lemmon MJ (1990) Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res 50: 7745-7749
84. Lartigau E and Guichard M (1995) Does tirapazamine (SR-4233) have any cytotoxic or sensitizing effect on three human tumour cell lines at clinically relevant partial oxygen pressure? Int J Radiat Biol 67: 211-216
85. Lambin P et al. (1992) The effect of the hypoxic cell drug SR-4233 alone or combined with the ionizing radiations on two human tumor cell lines having different radiosensitivity. Radiother Oncol 24: 201-204
86. Brown JM and Koong A (1991) Therapeutic advantage of hypoxic cells in tumors: A theoretical study. J Natl Cancer Inst 83: 178-185
87. Brown JM (1993) SR 4233 (tirapazamine): A new anticancer drug exploiting hypoxia in solid tumours. Br J Cancer 67: 1163-1170
88. Brown JIM (1999) The hypoxic cell: A target for selective cancer therapy - eighteenth Bruce F Cain Memorial Award lecture. Cancer Res 59: 5863-5870
89. Wouters BG et al. (2001) Mitochondrial dysfunction after aerobic exposure to the hypoxic cytotoxin tirapazamine. Cancer Res 61: 145-152
90. Patel M et al. (2003) Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates. J Neurooncol 61: 203-207
91. Hickman MJ and Samson LD (1999) Role of DNA mismatch repair and p53 in signaling induction of apoptosis by alkylating agents. Proc Natl Acad Sci USA 96: 10764-10769
92. Roos W et al. (2004) Apoptosis triggered by DNA damage 06-methylguanine in human lymphocytes requires DNA replication and is mediated by p53 and Fas/CD95/Apo-1. Oncogene 23: 359-367
93. Hermisson M et al. (2006) 06-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J Neurochem 96: 766-776
94. Wick W et al. (2002) Prevention of irradiation-induced glioma cell invasion by temozolomide involves caspase 3 activity and cleavage of focal adhesion kinase. Cancer Res 62: 1915-1919
95. Beauchesne P (2002) Promising survival and concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20: 3180-3181
96. Wedge SR et al. (1997) In vitro evaluation of temozolomide combined with X-irradiation. Anticancer Drugs 8: 92-97
97. van Rijn J et al. (2000) Survival of human glioma cells treated with various combination of temozolomide and X-rays. Int J Radiat Oncol Biol Phys 47: 779-784
98. Salama JK (2004) Intensity-modulated radiation therapy in gynecologic malignancies. Curr Treat Options Oncol 5: 97-108
99. Ma BB et al. (2003) Combined-modality treatment of solid tumors using radiotherapy and molecular targeted agents. J Clin Oncol 21: 2760-2776
100. Ang KK et al. (2004) Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy. Int J Radiat Oncol Biol Phys 58: 959-965
101. Pal SK and Pegram M (2005) Epidermal growth factor receptor and signal transduction: Potential targets for anti-cancer therapy. Anticancer Drugs 16: 483-494
102. Dent P et al. (1999) Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol Biol Cell 10: 2493-2506
103. Chinnaiyan P et al. (2005) Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res 65: 3328-3335
104. Bandyopadhyay D (1998) Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells. J Biol Chem 273: 1568-1573
105. Dittmann KH et al. (2001) Characterization of the amino acids essential for the photo- and radioprotective effects of a Bowman-Birk protease inhibitor-derived nonapeptide. Protein Eng 14: 157-160
106. Miles L et al. (2000) In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 6: 701-708
107. Bonner JA et al. (2000) Enhanced apoptosis with combination C225/ radiation treatment serves as the impetus for clinical investigation in head and neck cancers. J Clin Oncol 18 (Suppl): 47S-53S
108. Folkman J (2006) Angiogenesis. Annu Rev Med 57: 1-18
109. Jain RK (2005) Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307: 58-62
110. Wachsberger P et al. (2003) Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: Exploring mechanisms of interaction. Clin Cancer Res 9: 1957-1971
111. Murata R et al. (1997) An antiangiogenic agent (TNP-470) inhibited reoxygenation during fractionated radiotherapy of murine mammary carcinoma. Int J Radiat Oncol Biol Phys 37: 1107-1113
112. Mauceri HJ et al. (1998) Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 394: 287-291
113. Ning S et al. (2002) The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation. Radiat Res 157: 45-51
114. Hanna NN et al. (2000) Antitumor interaction of short-course endostatin and ionizing radiation. Cancer J 6: 287-293
115. Birchmeier C et al. (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4: 915-925
116. Lal B et al. (2005) Targeting the c-Met pathway potentiates glioblastoma responses to gamma-radiation. Clin Cancer Res 11: 4479-4486
117. Senzer N et al. (2005) Updated response and survival data for TNFerade combined with chemoradiation in the treatment of locally advanced pancreatic cancer (LAPC) [abstract #4097]. Presented at the 2005 ASCO annual meeting, Orlando, FL
118. Russo SM et al. (2001) Enhancement of radiosensitivity by proteasome inhibition: Implications for a role of NF-kappaB. Int J Radiat Oncol Biol Phys 50: 183-193
119. Shinohara ET et al. (2005) Enhanced radiation damage of tumor vasculature by mTOR inhibitors. Oncogene 24: 5414-5422
120. Nishimura Y (2004) Rationale for chemoradiotherapy. Int J Clin Oncol 9: 414-420
121. Pigott K et al. (1995) Where exactly does failure occur after radiation in head and neck cancer? Radiother Oncol 37: 17-19
122. Shukovsky LJ (1970) Dose, time, volume relationships in squamous cell carcinoma of the supraglottic larynx. Am J Roentgenol Radium Ther Nucl Med 108: 27-29
123. Cook JA et al. (2004) Oxidative stress, redox, and the tumor microenvironment. Semin Radiat Oncol 14: 259-266
124. Milosevic M et al. (2004) The human tumor microenvironment: Invasive (needle) measurement of oxygen and interstitial fluid pressure. Semin Radiat Oncol 14: 249-258
125. Roh HD et al. (1991) Interstitial hypertension in carcinoma of uterine cervix in patients: Possible correlation with tumor oxygenation and radiation response. Cancer Res 51: 6695-6698
126. Taghian AG et al. (2005) Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy: Clinical implications. J Clin Oncol 23: 1951-1961
127. Koukourakis MI et al. (2002) Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int J Radiat Oncol Biol Phys 53: 1192-1202
128. Suwinski R and Withers HR (2003) Time factor and treatment strategies in subdinical disease. Int J Radiat Biol 79: 495-502
129. Holsinger FC et al. (2003) Epidermal growth factor receptor blockade potentiates apoptosis mediated by Paclitaxel and leads to prolonged survival in a murine model of oral cancer. Clin Cancer Res 9: 3183-3189
130. Knecht R et al. (2003) EGFR antibody-supplemented TPE-chemotherapy: preclinical investigations to a novel approach for head and neck cancer induction treatment. Anticancer Res 23: 4789-4795
131. Niwa H et al. (2003) Antitumor effects of epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck. Clin Cancer Res 9: 5028-5035
132. Cohen EE (2005) Integration of Gefitinib (G), into a Concurrent Chemoradiation (CRT) Regimen Followed by G Adjuvant Therapy in Patients with Locally Advanced Head and Neck Cancer (HNC) - a Phase II Trial [abstract #5506]. J Clin Oncol 23 (Suppl): 16S